The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Oxidative stress-based therapeutics in COPD
Open accessAbstract
Oxidative stress is a major driving mechanism in the pathogenesis of COPD. There is increased oxidative stress in the lungs of COPD patients due to exogenous oxidants in cigarette smoke and air pollution and due to endogenous generation of reactive oxygen species by inflammatory and structural cells in the lung. Mitochondrial oxidative stress may be particularly important in COPD. There is also a reduction in antioxidant defences, with inactivation of several antioxidant enzymes and the transcription factors Nrf2 and FOXO that regulate multiple antioxidant genes. Increased systemic oxidative stress may exacerbate comorbidities and contribute to skeletal muscle weakness. Oxidative stress amplifies chronic inflammation, stimulates fibrosis and emphysema, causes corticosteroid resistance, accelerates lung aging, causes DNA damage and stimulates formation of autoantibodies. This suggests that treating oxidative stress by antioxidants or enhancing endogenous antioxidants should be an effective strategy to treat the underlying pathogenetic mechanisms of COPD. Most clinical studies in COPD have been conducted using glutathione-generating antioxidants such as N-acetylcysteine, carbocysteine and erdosteine, which reduce exacerbations in COPD patients, but it is not certain whether this is due to their antioxidant or mucolytic properties. Dietary antioxidants have so far not shown to be clinically effective in COPD. There is a search for more effective antioxidants, which include superoxide dismutase mimetics, NADPH oxidase inhibitors, mitochondria-targeted antioxidants and Nrf2 activators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Sies, H., Berndt, C., & Jones, D. P. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045037 · Cited by 3,520
Soriano, J. B., Abajobir, A. A., Abate, K. H., Abera, S. F., Agrawal, A., Ahmed, M. B., Aichour, A. N., Aichour, I., Aichour, M. T. E., Alam, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30293-x · Cited by 2,538
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Chronic obstructive pulmonary disease in non-smokers
Salvi, S. S., & Barnes, P. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61303-9 · Cited by 1,368
Self-citationThe Pathology of Chronic Obstructive Pulmonary Disease
Hogg, J. C., & Timens, W. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092145 · Cited by 845
Chronic obstructive pulmonary disease
Barnes, P. J., Burney, P. G. J., Silverman, E. K., Celli, B. R., Vestbo, J., Wedzicha, J. A., & Wouters, E. F. M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.76 · Cited by 734
Self-citationCorticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1564 · Cited by 694
Self-citation
Cited by
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
El Assar, M., Álvarez-Bustos, A., Sosa, P., Angulo, J., & Rodríguez-Mañas, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158713 · Cited by 371
Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries
Bezerra, F. S., Lanzetti, M., Nesi, R. T., Nagato, A. C., Silva, C. P. E., Kennedy-Feitosa, E., Melo, A. C., Cattani-Cavalieri, I., Porto, L. C., & Valenca, S. S. (2023) · Antioxidants · doi:10.3390/antiox12030548 · Cited by 336
Oxidative Stress in Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2022) · Antioxidants · doi:10.3390/antiox11050965 · Cited by 281
Self-citationOverview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases
Albano, G. D., Gagliardo, R. P., Montalbano, A. M., & Profita, M. (2022) · Antioxidants · doi:10.3390/antiox11112237 · Cited by 256
Metadata
- Authors
- Barnes, P. J.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 33
- Pages
- 101544
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W3016777912
- Cited by
- 497
- References
- 111
- FWCI
- 27.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxidative stress-based therapeutics in COPD. https://app.cochat.ai/papers/10.1016/j.redox.2020.101544
- The paper
- Barnes, P. J. (2020). Oxidative stress-based therapeutics in COPD. Redox Biology. https://doi.org/10.1016/j.redox.2020.101544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.